Analytical Data
-
Gene name
Thrombomodulin
- Application
-
Alternative Names
CD141; THBD; BDCA3; THRM; Fetomodulin
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by reducing SDS-PAGE.
-
Uniprot
O35370
-
Expression Region
Val31~Phe167
-
Molecular Weight
19kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Thrombomodulin (TM) is a multifunctional glycoprotein primarily expressed on the surface of endothelial cells, playing a crucial role in the regulation of coagulation and inflammation. Research into recombinant thrombomodulin (rTM) has gained momentum due to its therapeutic potential in various pathological conditions. TM acts as a cofactor for thrombin, converting it from a procoagulant enzyme into an anticoagulant that activates protein C, leading to the inactivation of factors Va and VIIIa and a subsequent reduction in thrombin generation. Beyond its anticoagulant properties, TM exhibits anti-inflammatory effects by modulating the endothelial cell response and inhibiting leukocyte adhesion, which is beneficial in diseases characterized by systemic inflammation and coagulopathy, such as sepsis and acute lung injury. The advent of recombinant DNA technology enables the production of rTM, offering advantages over traditional sources derived from human or animal tissues, including consistency, safety, and the ability to meet therapeutic demands. Recent studies have shown that rTM can improve survival rates in septic patients and reduce organ dysfunction, highlighting its promising role in critical care settings. Ongoing research aims to further elucidate the mechanistic pathways through which rTM exerts its protective effects and to evaluate its efficacy in various clinical populations. Consequently, rTM represents a novel therapeutic agent that could significantly alter the management of thrombotic and inflammatory disorders in modern medicine.
